Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481832 · ClinicalTrials.gov registry record · Phase 2
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00481832: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00481832 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00481832, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this trial is to develop an alternative treatment for patients with poor risk non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem cell transplant using the patient's own cells. This is followed with non-myeloablative transplant using stem cells from a related or unrelated donor to try and generate an anti-lymphoma response from the new immune system.
Primary Outcome
Event-free survival (EFS) as determined for participants who receive both planned transplants, for a minimum of 3 years. Events are defined as "disease progression/relapse" and "death of all causes".
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
- DRUG BCNU
- DRUG Filgrastim
- DRUG Antithymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-01 |
| Est. Completion | 2017-03-30 |
| Phase | Phase 2 |
Why NCT00481832 stopped before completion
NCT00481832 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00481832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00481832 about?
NCT00481832 is a clinical study titled "Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma". The purpose of this trial is to develop an alternative treatment for patients with poor risk non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem cell transplant using the patient's own cells. This is followed with non-myeloablative transplant using stem cells fr...
What is the current status of trial NCT00481832?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-01. Estimated completion is 2017-03-30.
What interventions are being tested in trial NCT00481832?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG), BCNU (DRUG), Filgrastim (DRUG), Antithymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT00481832?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00481832's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia